Author(s): Taraboletti G, Margosio B
Abstract Share this page
Abstract The great interest in the potential antineoplastic effect of targeting tumor-associated blood vessels has generated an expanding armamentarium of therapeutic tools that include antiangiogenic compounds, aimed at preventing the formation of vessels, and antivascular compounds, targeted to the existing tumor vasculature. Following promising preclinical studies, antiangiogenic drugs have rapidly gained access to clinical trials.
This article was published in Curr Opin Pharmacol
and referenced in Journal of Clinical & Experimental Pharmacology